Characterization of Human Cancer Cell Lines by Reverse-phase Protein Arrays

Akbani, 2014, A pan-cancer proteomic perspective on The Cancer Genome Atlas, Nat. Commun., 5, 3887, 10.1038/ncomms4887 Barretina, 2012, The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity, Nature, 483, 603, 10.1038/nature11003 Byers, 2013, An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance, Clin. Cancer Res., 19, 279, 10.1158/1078-0432.CCR-12-1558 Cancer Cell Line Encyclopedia Consortium, 2015, Pharmacogenomic agreement between two cancer cell line data sets, Nature, 528, 84, 10.1038/nature15736 Cheung, 2015, Regulation of the PI3K pathway through a p85alpha monomer-homodimer equilibrium, Elife, 4, e06866, 10.7554/eLife.06866 Daemen, 2013, Modeling precision treatment of breast cancer, Genome Biol., 14, R110, 10.1186/gb-2013-14-10-r110 Flaherty, 2012, Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations, N. Engl. J. Med., 367, 1694, 10.1056/NEJMoa1210093 Formisano, 2014, Epidermal growth factor-receptor activation modulates Src-dependent resistance to lapatinib in breast cancer models, Breast Cancer Res., 16, R45, 10.1186/bcr3650 Gao, 2014, Selective antitumor activity of ibrutinib in EGFR-mutant non-small cell lung cancer cells, J. Natl. Cancer Inst., 106, 10.1093/jnci/dju204 Garnett, 2012, Systematic identification of genomic markers of drug sensitivity in cancer cells, Nature, 483, 570, 10.1038/nature11005 Gygi, 1999, Correlation between protein and mRNA abundance in yeast, Mol. Cell Biol., 19, 1720, 10.1128/MCB.19.3.1720 Haibe-Kains, 2013, Inconsistency in large pharmacogenomic studies, Nature, 504, 389, 10.1038/nature12831 Haura, 2014, Deploying ibrutinib to lung cancer: another step in the quest towards drug repurposing, J. Natl. Cancer Inst., 106, 10.1093/jnci/dju250 Hennessy, 2010, A technical assessment of the utility of reverse phase protein arrays for the study of the functional proteome in non-microdissected human breast cancers, Clin. Proteomics, 6, 129, 10.1007/s12014-010-9055-y Hu, 2007, Non-parametric quantification of protein lysate arrays, Bioinformatics, 23, 1986, 10.1093/bioinformatics/btm283 Ince, 2015, Characterization of twenty-five ovarian tumour cell lines that phenocopy primary tumours, Nat. Commun., 6, 7419, 10.1038/ncomms8419 Ju, 2015, Development of a robust classifier for quality control of reverse-phase protein arrays, Bioinformatics, 31, 912, 10.1093/bioinformatics/btu736 Klijn, 2015, A comprehensive transcriptional portrait of human cancer cell lines, Nat. Biotechnol., 33, 306, 10.1038/nbt.3080 Leiserson, 2015, Pan-cancer network analysis identifies combinations of rare somatic mutations across pathways and protein complexes, Nat. Genet., 47, 106, 10.1038/ng.3168 Li, 2013, TCPA: a resource for cancer functional proteomics data, Nat. Methods, 10, 1046, 10.1038/nmeth.2650 Mani, 2008, The epithelial-mesenchymal transition generates cells with properties of stem cells, Cell, 133, 704, 10.1016/j.cell.2008.03.027 Marcotte, 2016, Functional genomic landscape of human breast cancer drivers, vulnerabilities, and resistance, Cell, 164, 293, 10.1016/j.cell.2015.11.062 Mertins, 2016, Proteogenomics connects somatic mutations to signalling in breast cancer, Nature, 534, 55, 10.1038/nature18003 Moghaddas Gholami, 2013, Global proteome analysis of the NCI-60 cell line panel, Cell Rep., 4, 609, 10.1016/j.celrep.2013.07.018 Monti, 2003, Consensus clustering: a resampling- based method for class discovery and visualization of gene expression microarray data, Mach. Learn., 52, 91, 10.1023/A:1023949509487 Nam, 2013, Antitumor activity of saracatinib (AZD0530), a c-Src/Abl kinase inhibitor, alone or in combination with chemotherapeutic agents in gastric cancer, Mol. Cancer Ther., 12, 16, 10.1158/1535-7163.MCT-12-0109 Nishizuka, 2003, Proteomic profiling of the NCI-60 cancer cell lines using new high-density reverse-phase lysate microarrays, Proc. Natl. Acad. Sci. USA, 100, 14229, 10.1073/pnas.2331323100 Seashore-Ludlow, 2015, Harnessing connectivity in a large-scale small-molecule sensitivity dataset, Cancer Discov., 5, 1210, 10.1158/2159-8290.CD-15-0235 Sheehan, 2005, Use of reverse phase protein microarrays and reference standard development for molecular network analysis of metastatic ovarian carcinoma, Mol. Cell Proteomics, 4, 346, 10.1074/mcp.T500003-MCP200 Singh, 2010, EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer, Oncogene, 29, 4741, 10.1038/onc.2010.215 Spurrier, 2008, Reverse-phase protein lysate microarrays for cell signaling analysis, Nat. Protoc., 3, 1796, 10.1038/nprot.2008.179 Stelzl, 2005, A human protein-protein interaction network: a resource for annotating the proteome, Cell, 122, 957, 10.1016/j.cell.2005.08.029 Szklarczyk, 2015, STRING v10: protein-protein interaction networks, integrated over the tree of life, Nucleic Acids Res., 43, D447, 10.1093/nar/gku1003 Tibes, 2006, Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells, Mol. Cancer Ther., 5, 2512, 10.1158/1535-7163.MCT-06-0334 Tyanova, 2016, Proteomic maps of breast cancer subtypes, Nat. Commun., 7, 10259, 10.1038/ncomms10259 Wu, 2015, Ibrutinib selectively and irreversibly targets EGFR (L858R, Del19) mutant but is moderately resistant to EGFR (T790M) mutant NSCLC Cells, Oncotarget, 6, 31313, 10.18632/oncotarget.5182 Yang, 2013, Predicting time to ovarian carcinoma recurrence using protein markers, J. Clin. Invest., 123, 3740, 10.1172/JCI74035 Yang, 2015, Integrative protein-based prognostic model for early stage endometrioid endometrial cancer, Clin. Cancer Res., 22, 513, 10.1158/1078-0432.CCR-15-0104 Zhang, 2014, Proteogenomic characterization of human colon and rectal cancer, Nature, 513, 382, 10.1038/nature13438 Zhang, 2016, Integrated proteogenomic characterization of human high-grade serous ovarian cancer, Cell, 166, 755, 10.1016/j.cell.2016.05.069